Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

EMA’s safety committee concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus & Wegovy: Amsterdam, The Netherlands Monday, June 9, 2 ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

European Medicines Agency (EMA)'s safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare eye condition that can lead to ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

The EMA’s drug safety committee launched a review of medicines containing semaglutide — the active ingredient in Ozempic, Wegovy and Rybelsus — in January.

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

Humans have spent thousands of years experimenting with weight loss aids. While Ozempic and Wegovy may be generating ...

Learn more about how Rybelsus compares with metformin. Rybelsus and Ozempic are both brand-name medications that contain the active ingredient semaglutide. Both are prescribed to help manage blood ...

I know we wanna cheat the system as Americans, we do,” the 53-year-old tells Page Six in an exclusive interview.